(HPA) axis (Wingenfeld, Spitzer, Rullkotter, & Löwe, 2010) . Enhanced basal cortisol concentrations and reduced feedback sensitivity have been frequent-ly but inconsistently reported in BPD. Carvalho Fernando and colleagues (2012) have found evidence for HPA axis involvement in the pathogenesis of BPD, suggesting neuroendocrine similarities to major depressive disor-der (MDD) by means of increased basal cortisol concentrations. But impor-tantly, despite elevated cortisol levels in the dexamethasone suppression test (DST), the hypothesized decrease in glucocorticoid (GC) feedback inhibition was not con rmed. Abnormalities in HPA axis challenge tests (such as the Dex-CRH suppression test) or altered circadian cortisol levels are frequently interpreted as indicators of dysfunction at the receptor level (i.e., glucocorti-coid receptor [GR] or mineralocorticoid receptor [MR] ). However, the mul-tiple systems involved in the complex regulatory feedback loop of the HPA axis complicate the interpretation in terms of receptor function. Intriguingly, human lymphocytes express mineralocorticoid and glucocorticoid recep-tors (Armanini, Endres, Kuhnle, & Weber, 1988) while the immune system is a major target of endogenous glucocorticoids (Baschant & Tuckermann, 2010) . Thus, immune cells can be used to directly examine steroid receptor function ex vivo. This approach has been used to study glucocorticoid sensi-tivity in psychiatric disorders and thus far increased as well as decreased sen-sitivity has been observed (Pariante, 2004; Rohleder, Wolf, & Wolf, 2010 ).
To our knowledge, studies of GC sensitivity in the immune system in the context of BPD have not yet been conducted. Therefore, we investigated steroid sensitivity of T cell responses as a potential biological substrate of BPD.
METHODS

SUBJECTS
Age-and education-matched female patients with BPD (n = 16) and healthy female control subjects (HC; n = 16) were recruited from the Department of Psychosomatic Medicine and Psychotherapy, Schön Klinik Hamburg Eilbek, or via local advertisement (posters at the University Hospital and via the Department home page) and received nancial remuneration. All subjects provided written informed consent. Physical health status was assessed by medical history and careful clinical examination by a staff physician.
Exclusion criteria were a history of severe somatic diseases (e.g., neuro-logical diseases), metabolic diseases (e.g., diabetes), endocrine disorders (e.g., Cushing's syndrome), immune-mediated diseases, hypertension, or current infections. Furthermore, pregnancy, current anorexia, current or lifetime schizophrenia, alcohol or drug dependence, bipolar disorder, schizoaffec-tive disorder, major depression with psychotic symptoms, attention-de cit/ hyperactivity disorder, and cognitive impairment resulted in exclusion. The study was approved by the Ethics Committee of the Chamber of Physicians, Hamburg, Germany.
CLINICAL ASSESSMENTS
Patients underwent structured clinical interviews administered by trained psychologists (J.G., K.W.) (Structured Clinical Interview for DSM Disor-ders; SCID; First, Spitzer, Gibbon, & Williams, 1996) . Furthermore, patients completed German versions of the Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) , the Posttraumatic Diagnostic Scale (PDS; Foa, 1995) , and the Borderline Symptom List (BSL; Bohus et al., 2007) . To screen for childhood maltreatment, the German Childhood Trau-ma Questionnaire (CTQ; Klinitzke, Romppel, Häuser, Brähler, & Glaesmer, 2012) was administered.
STEROID SENSITIVITY ASSAY
All blood samples were taken between 8:30 and 9:30 a.m. and processed immediately for cryopreservation. Samples were processed according to standard operating procedures of the biobank of the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (Inims). Peripheral blood mononuclear cells (PBMCs) were isolated using the Ficoll-Hypague method and cryopreserved until assayed. After density centrifugation, PBMCs were resuspended in a stepwise procedure in medium 1 (RPMI-1640 + 10% FCS) and medium 2 (40% RPMI-1640, 40% FCS, 20% DMSO) at a concentra-tion of 10 7 viable PBMCs per aliquot (1 mL) and then slowly frozen at an optimal cooling rate of −1°C/minute using Mr. Frosty® freezing containers (ThermoFisher Scienti c, Waltham, MA). After overnight cooling, aliquots were moved to an N2 storage facility (−180°C). Using this procedure, vi-ability of cells as determined by tryphan blue staining is > 95% for storage times of up to 5 years. For the current study, maximum storage time was 7 months. Samples from BPD patients and HC were run in parallel using the same batch of reagents. Functional steroid sensitivity of T cell function was assessed as previously described (Fischer et al., 2012) . Cells were seeded at 2 × 10 6 viable cells/mL in RPMI-1640 (PAA Laboratories, Pasching, Austria) supplemented with 2 mM Lglutamine and penicillin/streptomycin and stim-ulated with phytohemagglutinin (PHA) at a concentration of 1 μg/mL alone or in combination with one of seven concentrations of the agonists dexa-methasone (10 -12 M to 10 -6 M), aldosterone, or hydrocortisone (each 10 -11 M to 10 -5 M). PBMCs were incubated (37°C, 5% CO 2 ) for 48 hours and then pulsed with 1 μCi/well [methyl-
3 H]thymidine. After another 24 hours, cells were harvested with a Tomtec Harvester 96® Mach III M (Tomtec, Inc., Hamden, CT), and thymidine incorporation was determined by liquid scin-tillation (Wallac 1450 microbeta, Trilux, PerkinElmer, Rodgau, Germany). Results were averaged from triplicate wells for each condition expressed as counts per minute (cpm).
STATISTICAL ANALYSIS
The inhibitory concentration 50 (IC-50) values representing concentrations inhibiting 50% of the PHA-induced proliferation for each subject and ago- nist were determined by nonlinear sigmoidal curve tting utilizing Prism® Software as described by Fischer et al. (2012) . All variables were tested for normality and equality of variance. Student t tests were conducted in order to detect differences between the BPD and healthy control (HC) groups us-ing PASW Statistics 18 software, with p values < 0.05 considered signi cant.
RESULTS
Patients with BDP and HC were well matched for age, body height, and weight, while there was a marginally signi cant difference for smoking (Ta-ble 1). In the patient group, patients met, on average, six of the DSM-IV cri-teria for BPD. In addition, eight BPD patients met DSM-IV criteria for MDD and six were diagnosed with PTSD (Table 1 ). Four of these BPD patients had both comorbidities. While seven of the BDP patients were untreated, several participants in the patient group were taking psychotropic medication. These included atypical antipsychotics (Quentiapine, n = 4; Olanzapine, n = 1) as well as antidepressive treatment (noradrenergic and speci c serotonergic antidepressants, n As expected, BPD patients had signi cantly higher scores on self-report measures of depression (BDI), childhood trauma (CTQ), and PTSD (PDS) compared to HC. There were no signi cant differences between BPD and HC in T cell steroid sensitivity as measured by IC-50 values with any of the three agonists (see Table 1 and Figure 1) . Exploratory analyses revealed 
DISCUSSION
To our knowledge, this is the rst study assessing steroid sensitivity in the immune system in the context of BPD. Our results indicate no apparent alterations in T cell steroid sensitivity in BPD. As expected, MDD and PTSD comorbidity was frequent in the patient group. However, GC sensitivity was not associated with depressive symptoms, PTSD severity, or early life stress (ELS). The cortisol suppression capacity in the DST is considered a mea-sure of the HPA axis GR-mediated negative feedback function. HPA axis hyporesponsiveness with lower basal cortisol levels and pronounced cortisol suppression in the DST have also been reported in BPD, but the majority of studies support the notion of a hyperreactive HPA system (Carvalho Fer-nando et al., 2012) . Furthermore, HPA hyperresponsiveness as measured by the Dex-CRH test was found in BPD patients with a history of chronic abuse in early childhood (Rinne et al., 2002) . The authors hypothesized that ELS accounts for this altered HPA state in BPD. Importantly, Carvalho Fernando et al. (2012) have found increased cortisol levels in the DST in BPD, as well as an association between cortisol release and childhood trauma. In contrast to basal and stimulated cortisol (i.e., regulation of the HPA axis itself), we did not nd evidence for an association between childhood trauma and GC sensitivity in peripheral immune cells (i.e., a major target tissue of endog-enous glucocorticoids). Our data suggest that GC sensitivity of T cell func-tion is unaltered in BDP, which may indicate a tissue-speci c dysregulation of steroid signaling. In vitro inhibition of cell proliferation has previously been used to reveal differences in GC sensitivity of T cells as a biological substrate of depressive symptoms in patients with multiple sclerosis, a neuro-in ammtory disease of presumably T cell-driven origin (Fischer et al., 2012) . Similarly, studies have shown altered GC sensitivity of T cell proliferation in patients with PTSD (de Kloet et al., 2007) and major depression (Lowy, Reder, Gormley, & Meltzer, 1988; Wodarz et al., 1991) . This would suggest that the assay system is speci c and sensitive to pick up GC sensitivity differ-ences in T cell function in autoimmune and psychiatric disorders, but that T cell regulation by GCs is unaltered in BPD. However, our results do not rule out the possibility that other immune cell subpopulations of the innate (e.g., monocytes, NK cells) or adaptive immune system (e.g., B cells) may show al-tered GC regulation in BPD. This remains to be elucidated with appropriate functional assay systems.
BPD is a very heterogeneous disorder, and it becomes increasingly clear that comorbidities and clinical features such as trauma history may have variable, interacting in uences on the neuroendocrine pro le in BPD (Zim-merman & Choi-Kain, 2009 ). However, GC sensitivity measures were not correlated to severity of depression, severity of PTSD symptoms, or CTQ scores in our study. It has been previously reported that elevated free cor-tisol levels in BPD patients are positively correlated to MDD severity and negatively associated with PTSD symptomatology (Wingenfeld, Driessen, Adam, & Hill, 2007) . In a longitudinal study, DST results were identi ed as a stable marker of abnormal HPA axis function in BPD with comorbid PTSD, resulting in more pronounced suppression (Wingenfeld, Lange, et al., 2007) . In another study, it was shown that acute hydrocortisone administra-tion had bene cial effects on hippocampus-relevant memory in BPD, while in healthy controls hydrocortisone impaired memory retrieval (Wingenfeld et al., 2013) . These results were interpreted in terms of a cortisol-induced enhancement of hippocampal functioning, which might be related to a sen-sitization of GR function. Possibly, in BPD, altered GR function might be more tissue speci c and restricted to CNS GR (e.g., in the hippocampus and hypothalamus) as well as the pituitary.
The present study has several limitations. Due to the small sample size, lack of power is obviously an issue, and the absence of statistically signi cant differences could re ect this fact rather than absence of a biological effect. Therefore, we have also provided effect sizes, which were all well below the accepted thresholds for small effects (Table 1 ). In addition, the overlapping steroid sensitivity curves and the small error bars observed (Figure 1) argue against a biologically signi cant effect. Given these considerations and the very low effect sizes obtained in this pilot study, we believe that BPD is un-likely to be linked to altered steroid sensitivity of T cell responses. In addi-tion, in this small pilot study, we did not obtain measures of GC regulation in other systems, most notably in the HPA axis itself. Therefore, future studies should assess HPA axis regulation (such as the Dex-CRH test) in parallel with functional assays of GC sensitivity in important target tissues of endog-enous cortisol, such as cells of the innate and adaptive immune system.
In conclusion, our study suggests unaltered GC sensitivity in T cells in BPD, a major compartment of the adaptive immune system.
